default author photo

Elizabeth J. Davis

Vanderbilt University - Vanderbilt-Ingram Cancer Center

1211 Medical Center Dr

Nashville, TN 37232

United States

SCHOLARLY PAPERS

1

DOWNLOADS

64

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer

Number of pages: 40 Posted: 30 May 2024
affiliation not provided to SSRN, University of Kansas - Cancer Center, affiliation not provided to SSRN, INCLIVA Biomedical Research Institute, University of Michigan at Ann Arbor, Fred Hutchinson Cancer Research Center - Clinical Research Division, Vanderbilt University - Vanderbilt-Ingram Cancer Center, Netherlands Cancer Institute, Northwestern University - Northwestern Memorial Hospital, Brown University, Emory University - School of Medicine, INCLIVA Biomedical Research Institute, Vanderbilt University - Division of Hematology and Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Brown University
Downloads 64 (924,743)

Abstract:

Loading...

GSK-3β Inhibitor, elraglusib (9-ING-41), pancreatic cancer, combination, previously untreated